Login to Your Account


When going after macrophages, "in my view, you play directly with the immune system," said Maxime Ranger, president and CEO of Mperia Therapeutics Inc., which is advancing macrophage-targeting immunotherapies.

Frequency Therapeutics Inc., a company working to develop a progenitor cell-activating hearing restoration therapy, has closed a $32 million series A financing led by Cobro Ventures.

Intezyne Technologies Inc. should find itself “on an IPO trajectory for late 2018 or early 2019,” its chief financial officer (CFO), Russell McAllister, told BioWorld Today, “coinciding with potential licensing deals for both” lead candidates owned by the Tampa, Fla.-based company.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: